Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Income from Continuing Operations (2016 - 2026)

Ocular Therapeutix has reported Income from Continuing Operations over the past 14 years, most recently at 90067000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 42.79% year-over-year to 90067000.0; the TTM value through Mar 2026 reached 290489000.0, down 47.9%, while the annual FY2025 figure was 263497000.0, 59.62% down from the prior year.
  • Income from Continuing Operations for Q1 2026 was 90067000.0 at Ocular Therapeutix, down from 65249000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 19498000.0 in Q1 2022 and troughed at 90067000.0 in Q1 2026.
  • A 5-year average of 40779705.88 and a median of 31746000.0 in 2024 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: grew 10.95% in 2022 and later crashed 115.51% in 2024.
  • Year by year, Income from Continuing Operations stood at 20785000.0 in 2022, then decreased by 9.42% to 22742000.0 in 2023, then crashed by 115.51% to 49011000.0 in 2024, then plummeted by 33.13% to 65249000.0 in 2025, then tumbled by 38.04% to 90067000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for OCUL at 90067000.0 in Q1 2026, 65249000.0 in Q4 2025, and 67971000.0 in Q3 2025.